ABVC BioPharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABVC research report →
Companywww.abvcpharma.com
ABVC BioPharma, Inc. , a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.
- CEO
- Uttam Yashwant Patil
- IPO
- 2004
- Employees
- 16
- HQ
- Fremont, CA, US
Price Chart
Valuation
- Market Cap
- $15.94M
- P/E
- -3.89
- P/S
- 0.00
- P/B
- 2.60
- EV/EBITDA
- -2.67
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -70.28%
- ROIC
- -42.90%
Growth & Income
- Revenue
- $0 · 56.19%
- Net Income
- $-7,908,554 · -61.30%
- EPS
- $-0.39 · 7.14%
- Op Income
- $-7,151,259
- FCF YoY
- -65.39%
Performance & Tape
- 52W High
- $5.48
- 52W Low
- $0.88
- 50D MA
- $1.18
- 200D MA
- $2.16
- Beta
- 0.42
- Avg Volume
- 92.14K
Get TickerSpark's AI analysis on ABVC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 20, 22 | Jiang Shuling | other | 0 |
| Aug 2, 21 | An Chihliang | other | 0 |
| Aug 2, 21 | Sakamoto Norimi | other | 0 |
| Aug 2, 21 | Odaira Yoshinobu | other | 0 |
| Aug 2, 21 | Jiang Tsung Shann | other | 0 |
| Aug 2, 21 | Miao Shin-Yu | other | 0 |
| Nov 8, 21 | Tseng Shih-Chen | other | 0 |
| Aug 2, 21 | Jiang Eugene | other | 0 |
| Aug 2, 21 | Jiang Chang-Jen | other | 0 |
| Aug 2, 21 | King Chi-Hsin Richard | other | 0 |
Our ABVC Coverage
We haven't published any research on ABVC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ABVC Report →